D2C7 / Istari Oncology 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
D2C7 / Istari Oncology
NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting
1/2
50
US
D2C7-IT, 2141-V11
Darell Bigner, Rockefeller University
Newly Diagnosed MGMT Unmethylated Glioblastoma
02/26
02/28
NCT02303678: D2C7 for Adult Patients With Recurrent Malignant Glioma

Completed
1
81
US
D2C7-IT
Darell Bigner
Malignant Glioma, Brain Tumor, Recurrent
05/19
03/24
NCT04160494: D2C7-IT With Atezolizumab for Recurrent Gliomas

Active, not recruiting
1
18
US
D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), Tecentriq, D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Darell Bigner, Istari Oncology, Inc., National Cancer Institute (NCI), Genentech, Inc.
Malignant Glioma
12/24
12/27
NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting
1
30
US
D2C7-IT, 2141-V11, anti-CD40
Darell Bigner, Rockefeller University
Glioma, Malignant
12/24
12/25
NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in rGBM

Not yet recruiting
1
46
US
D2C7-IT, 2141 V11
Darell Bigner, Rockefeller University
Recurrent Glioblastoma IDH Wildtype
01/29
01/30

Download Options